Pub. Date : 2020 Oct 17
PMID : 33069237
3 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer. | CUDC-907 | poly(ADP-ribose) polymerase 1 | Homo sapiens |
| 2 | Furthermore, we showed that CUDC-907 treatment enhanced the therapeutic efficacy of PARP inhibitor olaparib in SCLC cellular models and a PDX model. | CUDC-907 | poly(ADP-ribose) polymerase 1 | Homo sapiens |
| 3 | CONCLUSIONS: Our study uncovers that dual PI3K and HDAC inhibition by CUDC-907 exerts significant single-agent activity and strong synergistic effects with PARP inhibitor olaparib in SCLC, which thus provides a rational combination treatment strategy for SCLC clinical investigation. | CUDC-907 | poly(ADP-ribose) polymerase 1 | Homo sapiens |